Galanin (2-30) acid

WTLNSAGYLLGPHAVGNHRSFSDKNGLTS-acid

  • Description

  • Application Data

Description

Galanin (2-30) acid form is a full agonist for the galanin receptor GalR2; galanin is a widely distributed neuropeptide with a wide variety of roles, including energy homeostasis and mental health.

See full description

Application Data

Catalogue number crb1001318
Molecular Weight 3098.5
Sequence (one letter code)

WTLNSAGYLLGPHAVGNHRSFSDKNGLTS-acid

Sequence (three letter code)

H-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-Ser-OH

Purity >95%
Storage -20°C
References

Church et al., (2002). Molecular modelling and site-directed mutagenesis of human GALR1 galanin receptor defines determinants of receptor subtype specificity. Protein Eng. Des. Sel., 15(4): 313. doi: 10.1093/protein/15.4.313.

Fang et al., (2017). Regulatory effects of galanin system on development of several age related chronic diseases. Exp. Gerontology, 95: 88. PMID: 28450241.

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Galanin is predominantly an inhibitory neuropeptide expressed in humans and other mammals’ brains, spinal cords, and gut. Galanin signalling occurs through three G protein-coupled receptors GalR1-3. Galanin has been implicated in many biologically diverse functions, including nociception, waking and sleep regulation, cognition, feeding, mood regulation and blood pressure regulation. Galanin appears to have neuroprotective activity as its biosynthesis is increased 2-10 fold upon axotomy and during seizure activity in peripheral tissues and the brain.

The clinical relevance of galanin is related to several chronic neural disorders, including Alzheimer’s disease, epilepsy, depression and cancer; those who suffer from type 2 diabetes mellitus, depression and Alzheimer’s disease often express high levels of galanin. Conversely, intervention with galanin agonists (for example, M617, M1145 and M1153) were able to ameliorate disease symptoms such as Alzheimer’s and have pro-nociceptive effects. Specifically, activation of GAL2 can alleviate such disease features in human and rodent models. This galanin (2-30) peptide has been used to characterise galanin’s binding sites and affinity for GALR receptors via competition binding analysis. Galanin (2-30) is a full agonist of the GALR2 receptor compared to its affinity for GALR1.

Galanin (2-30) acid

Cat No.Pack SizePriceQty.
0.5mg£170.00
1mg£220.00
Bulk Quote

You may also like…